alexa Improving Adverse Event Following Immunization Reporting In Africa
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

6th World Pharmacists and Clinical Pharmacy Annual Congress
May 22-23, 2017 Chicago, USA

Peter Yamoah
University of KwaZulu Natal, South Africa
Posters & Accepted Abstracts: J Clin Trials
DOI: 10.4172/2167-0870-C1-014
Globally, the burden of adverse drug reactions is huge as they are the fourth to sixth leading cause of deaths among hospitalized patients. The WHO developed strategies to ensure that adverse events relating to drugs are traced following the thalidomide disaster in the 1960s. Key among these strategies was the establishment of the WHO Program for International Drug Monitoring (PIDM). Although the PIDM started in 1968, the first African countries joined in 1992, and by 30th September 2015, a total of 35 of 54 African countries were full members of the PIDM. Not until the early 2000s, Pharmacovigilance was not much of a priority science to Africa compared to the developed world for several reasons including poor legislation for medicine regulation, lack of access to medicines and health commodities, weak and uncoordinated supply chains for medicinal products, lack of knowledge and awareness of Pharmacovigilance and lack of financial, human and technical resources. Even though most of these challenges have been addressed over the years, Adverse Drug Reaction reports have not significantly increased in momentum in Africa. A less researched area in Pharmacovigilance in Africa is the adverse events related to immunization even though the use of vaccines continues to increase in Africa. Results from the WHO adverse drug reaction database, Vigibase reveals that Africa contributes to only 1% of AEFI reports worldwide. This is a worrying trend which needs to be addressed with all seriousness. This could be achieved by the implementation of the Global Vaccine Safety Blueprint developed by the WHO. This blueprint has 8 strategic objectives including detection of AEFI, adequate investigation of safety signals, adequate communication of vaccine safety issues, use of appropriate tools and methods, ensuring a regulatory framework is in place, technical support and training, global analysis and response and public-private information exchange

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version